Meta AnalysisID 5629
艾迪注射液联合培美曲塞和铂类化疗治疗III/IV期非小细胞肺癌的疗效与安全性：随机对照试验的系统评价与Meta分析方案
CRD42022328666
Aidi injection (ADI) is a commonly used anti-cancer Chinese patent medicine, which can reduce various adverse reactions caused by chemotherapy, and can also enhance immunity, and has long been prescribed as adjunctive tr
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 5629
- Evidence Id
- 14187
- Core Evidence Id
- 14187
- Source Meta Analysis Id
- 5612
- Herb2 Meta Analysis Id
- HBMA005612
- Crd Id
- CRD42022328666
- Title
- Effificacy and safety of Aidi injection combined with pemetrexed and platinum chemotherapy for stage III/IV non-small cell lung cancer:A protocol for systematic review and meta-analysis of randomized controlled trials
- Review Question
- Aidi injection (ADI) is a commonly used anti-cancer Chinese patent medicine, which can reduce various adverse reactions caused by chemotherapy, and can also enhance immunity, and has long been prescribed as adjunctive treatment with Pemetrexed and Platinum Chemotherapy (PPC) in patients with stage III/IV non-small cell lung cancer(NSCLC). However, the efficacy and safety of this combination therapy remain unclear.
- Study Type Included
- (1) Randomized controlled trials without language restrictions were included in this study. (2) This study investigated the effificacy and safety of Aidi injection combined with pemetrexed and platinum chemotherapy for stage III/IV non-small cell lung cancer
- Condition Being Studied
- Non-small cell lung cancer
- Participant
- Patients with a definite diagnosis of stage III (unresectable) or stage IV NSCLC. There were no restrictions on age, sex, and race.
- Animal
- Human Disease Modelled
- Intervention
- All patients who received Aidi injection combined with pemetrexed and platinum chemotherapy for NSCLC were included in this study.
- Comparator Control
- pemetrexed and platinum chemotherapy
- Main Outcome
- (1) Immune function evaluation: CD3+, CD4+, CD8+, and CD4+/CD8+ cell ratios. (2) Quality of life assessment: Karnofsky score (Karnofsky performance ancestatus, KPS) was used as the standard to assess the quality of life in both groups. (3)According to the Guidelines for Clinical Research of New Chinese Medicines [31], The TCM clinical syndromes in the two groups of patients were evaluated according to the Guidelines for Clinical Research of New Chinese Medicines.
- Outcome Measure
- Additional Outcome
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Meta-Analysis as Topic; Pemetrexed; Platinum; Randomized Controlled Trials as Topic; Systematic Reviews as Topic
- Contact
- Huan Ding [email protected]
- Organisational Affiliation
- Changchun University of Chinese Medicine
- Funding Source
- This study was supported by the Project Agreement for Science & Technology Development, Jilin Province Grant number(s) <span style=font-size: 14px>State the funder, grant or award number and the date of award</span> 20200404060YY
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-04-30
- Registration Date
- 2022-05-10
- Anticipated Start Date
- 2022-04-27
- Anticipated Completion Date
- 2023-04-27
- Title Cn
- 艾迪注射液联合培美曲塞和铂类化疗治疗III/IV期非小细胞肺癌的疗效与安全性：随机对照试验的系统评价与Meta分析方案
- Title En
- Effificacy and safety of Aidi injection combined with pemetrexed and platinum chemotherapy for stage III/IV non-small cell lung cancer:A protocol for systematic review and meta-analysis of randomized controlled trials
- Bilingual Status
- complete